Monday , October 23 2017
Home / Letter From The Editor / June 16, 2016

June 16, 2016

dave

Steve, Joy and I had full days at the ADA Scientific meeting last week. Steve and Joy were busy interviewing key opinion leaders and researchers, and I was combing the posters and abstracts looking for the latest data that affects your practice — and possibly your choice of medications. There were plenty of studies on new classes of drugs that might have some promise in the future, but the class that we now use that got the most attention was the SGLT-2 inhibitors. We culled through the over 150 posters and abstracts to grab some of the most important ones for you to review this week.

Dave Joffe
Editor-in-chief